Endoscopic stomach procedure with lifestyle changes for obesity and fatty liver inflammation
Compares a minimally invasive stomach-shrinking procedure plus lifestyle changes against lifestyle changes alone.
Key facts
- Who runs it
- Pichamol Jirapinyo, MD, MPH
- Where
- Boston and Morgantown, United StatesSee the 2 sites
- Trial code
- Registry title
- Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial
- Status
- Recruiting
- People taking part
- 132 people, planned
- Started
- 24 Jun 2025
- Expected to end
- Jun 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- ESG + lifestyle modification
- Lifestyle modification
- Record updated
- 25 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with obesity who have a fatty liver condition (MASH). It compares a stomach-reducing procedure plus lifestyle changes with lifestyle changes alone.
- Age
- 18 years or older
- Sex
- Men and women can join
- Disease stage
- Obesity with BMI of 30 kg/m2 or more, or 27 kg/m2 or more with at least one obesity-related condition. The trial studies fatty liver disease (MASH).
- Earlier treatment
- Weight must have been stable (no change over 5%) for 6 months. People must not start a new anti-obesity medicine for 12 months. People cannot join if they had vitamin E (800 IU/day or more), pioglitazone, obeticholic acid or resmetirom in the 90 days before the first visit, or had weight-loss surgery or this procedure before.
Main reasons for not taking part
- Other chronic liver diseases, liver cirrhosis or liver failure
- Earlier stomach or bowel surgery (some simple operations are allowed), or earlier weight-loss surgery
- Insulin-dependent diabetes, or HgbA1C of 12% (108 mmol/mol) or more
- Pregnant or breastfeeding, active smoking, or heavy alcohol use
- Severe reflux, stomach or gullet diseases, or eating disorders
The registry criteria, word for word
Show all 37 criteriaShow less
Who can take part
- Age ≥ 18 (male or female)
- BMI ≥30 kg/m2 or ≥27 kg/m2 with at least one obesity-related comorbidity
- Self-reported stable weight (no weight change >5%) for 6 months prior to the first study visit
- Willingness to follow protocol requirements, including signed informed consent, routine follow-up schedule, completing laboratory/imaging/additional tests, and completing diet counseling
- Willingness to NOT start a new anti-obesity medication for the following 12 months
- Residing within a reasonable distance from the investigator's office and able to travel to the investigator to complete routine follow-up visits
- Ability to give informed consent
- Women of childbearing potential (i.e., not post-menopausal, nor surgically sterilized) must agree to use adequate birth control methods
Who cannot take part
- Treatment with vitamin E (at doses ≥800 IU/day), pioglitazone, obeticholic acid, or resmetirom <90 days before the first study visit
- Prior bariatric surgery
- Prior endoscopic sleeve gastroplasty
- Patients on corticosteroids, immunosuppressants, or narcotics
- Known history of other chronic liver diseases (viral hepatitis, autoimmune hepatitis, drug-induced hepatitis, and genetic)
- History of foregut or gastrointestinal (GI) surgery (except uncomplicated fundoplication, cholecystectomy or appendectomy)
- Any inflammatory disease of the GI tract, including severe (LA Grade C or D) esophagitis, Barrett's esophagus with dysplasia, gastric ulceration, duodenal ulceration, cancer or specific inflammation such as Crohn's disease
- Potential upper gastrointestinal bleeding conditions such as esophageal or gastric varices, congenital or acquired intestinal telangiectasis, or other congenital anomalies of the gastrointestinal tract such as atresias or stenoses
- Severe gastroesophageal reflux disease (GERD)
- Achalasia or any other severe esophageal motility disorder
- Hepatic insufficiency or cirrhosis
- Insulin-dependent diabetes (either type 1 or type 2) or a significant likelihood of requiring insulin treatment in the following 12 months or HgbA1C ≥ 12%
- Patients on an anti-seizure or anti-arrhythmic medication
- History of poorly controlled hypertension, coronary artery disease, congestive heart failure, cardiac arrhythmia
- History of respiratory diseases such as chronic obstructive pulmonary disease (COPD) requiring steroids, pneumonia, or cancer
- History of autoimmune connective tissue disorder such as lupus, scleroderma or immunocompromised disease
- History of active malignancy
- History of genetic or hormonal causes for obesity, such as Prader Willi syndrome
- History of endocrine disorders affecting weight, such as uncontrolled hypothyroidism
- Eating disorders, including night eating syndrome, bulimia, binge eating disorder or compulsive overeating
- Patients on an anti-platelet agent, anticoagulant agent or chronic/routine use of NSAIDs
- A structural abnormality in the esophagus or pharynx, such as a stricture or diverticulum, that could impede passage of the endoscope
- Chronic abdominal pain
- Gastroparesis or intractable constipation
- Severe coagulopathy
- Patients who are pregnant or breastfeeding
- Excessive alcohol consumption (>20 g per day for women; >30 g per day for men)
- Active smoking
- Active psychological issues preventing participation in a lifestyle modification program as determined by a psychologist
Where in United States
- Brigham and Women's HospitalBoston, United StatesContact: Michele B. Ryan, MSTaking people
- West Virginia UniversityMorgantown, United StatesContact: Soban ResearcherTaking people
About the trial
What the trial wants to find out
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease globally. While weight loss through lifestyle modification is the standard treatment, most patients regain weight limiting ultimate improvement in liver disease. On the other end of the spectrum, bariatric surgery has shown promise in the treatment of MASLD/metabolic dysfunction-associated steatohepatitis (MASH) due to its efficacy in inducing weight loss. Nevertheless, its adoption has been hindered by the perceived invasiveness of surgery.
Read full original descriptionShow less
Over the past decade, endoscopic sleeve gastroplasty (ESG) has gained recognition as a promising minimally-invasive approach to weight loss. The procedure involves utilizing a Food and Drug Administration (FDA)-authorized endoscopic suturing device to reduce the gastric volume by 70%. Studies reveal that ESG is associated with approximately 18.2% weight loss at one year after the procedure, with sustained results for at least 10 years. Nevertheless, the effect of ESG on MASH remains unknown.
In this study, the investigators will compare ESG + lifestyle modification versus lifestyle modification alone in treating histologic MASH. The study will randomize patients to one of two different treatment options: ESG + lifestyle modification or lifestyle modification alone.
The 2 groups in the trial
- ESG + lifestyle modificationTreatment being tested
Endoscopic sleeve gastroplasty weight loss procedure with a lifestyle modification program for 12 months.
Treatment: ESG + lifestyle modification and Lifestyle modification
- Lifestyle modificationExisting treatment, for comparison
Lifestyle modification program for 12 months.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effect of Endoscopic Sleeve Gastroplasty on Patients With Obesity and Concomitant Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Multicenter, Open-label, Randomized Controlled Trial
- Plain-language title
- Endoscopic stomach procedure with lifestyle changes for obesity and fatty liver inflammationGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 25 June 2026